Drugs / LDP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03908814 | Apr 2019 → Apr 2023 | — | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LDP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03908814 ↗ |
| Action | Inhibit | “Anti-PD-L1” NCT03908814 ↗ |
| Modality | Monoclonal antibody | “Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)” NCT03908814 ↗ |